Your Exclusive
Invitation to take part in an
For the complete Intellectual Property Ownership of the
Positive and Negative Syndrome Scale™ (PANSS™)
• Quality Results • Trusted Reputation • Standard of Excellence
You are invited to participate in an exclusive auction for The Positive and Negative Syndrome Scale™ (PANSS™) suite of products. The PANSS represents a gold-standard in assessment of symptom presence and severity in schizophrenia and for the first time it’s available to own along with the SCI-PANSS and the IQ-PANSS accompaniments. No longer will you need permissions/licensing to use it in drug and clinical trials. Better yet, control who you allow to access this in-demand assessment. Act now to secure your rights to this powerful tool.
Auction Details
Expressions of interest and bids can be submitted between June 30 and July 15, 2016. Auction closes August 19, 2016. Please contact Clinton Agius for further details and/ or to place a bid.
PANSS Overview
OTHER**
3.18%
27.65% PAPER BASED
PROFIT MARGIN
84.99%
6.34%
COST OF GOODS
HEALTHCARE*
72.35%
PERMISSIONS & LICENSING
15.01%
22.70%
Figure 2.0
CONTRACT RESEARCH ORGANIZATION
Figure 3.0
67.78%
PANSS Profitability
PHARMACEUTICAL
PANSS Delivery Method
Figure 1.0
PANSS Client Mix
The Positive and Negative Syndrome Scale (PANSS)™ provides a broad-based, standardized evaluation of psychopathology dimensions that help to characterize the patient’s clinical profile and to monitor changes with treatment. The PANSS is based on findings that schizophrenia comprises at least two distinct symptom domains: the positive symptom consisting of productive symptoms, such as hallucinations and delusions, usually responding well to neuroleptic treatment; and the negative symptoms consisting of deficit features, such as blunted affect and passive social withdrawal, indicative of poor premorbid status, neuroleptic resistance, and poor prognosis.
* Healthcare includes: Biotechnology, HMO, Hospitals, Mental Health Clinics, and Private Practice ** Other includes: University, Government, and Distibutor
A Trusted Asset
The PANSS is the most researched and widely used assessment of symptom presence and severity in schizophrenia. It is used as an outcome measure in numerous FDA approved clinical trials as well as in private practice and hospital settings (see figure 1.0). After nearly 30 years of use, the PANSS has cultivated a reputation for excellence which, coupled with its exceptional margins, makes it a highly profitable tool (see figure 3.0). Research with the PANSS has found the instrument to be highly reliable and valid, and the positive-negative and other symptom scales to be significantly related to differences along historical, genealogical, psychometric, clinical, psychopharmacological, and prognostic variables.
Quick Reference Age 18 and older
Number of Items PANSS: 33 SCI-PANSS: 179 IQ-PANSS: 14
Administration Time PANSS: varies SCI-PANSS: 30-40 minutes IQ-PANSS: varies
Qualification Level B-level
Format Handscored Permissions Licensing
Additional Resources Available PANSS Technical Manual PANSS QuikScore Forms
COUNTRIES Where PANSS is Used and/or Translated The PANSS has been well documented with over 12,000 citations in scientific literature. The assessment has been used in over 1,500 clinical studies by over 200 Pharmaceutical & Clinical Research Organizations in more than 40 countries (see figure 4.0). Figure 4.0
The PANSS in Practice Drug Efficacy: The PANSS is used in clinical trials as a primary and secondary outcome measure for drug efficacy. PTSD: The assessment is used to investigate the link between PTSD symptoms (agitation and psychotic symptoms) and platelet monoamine oxidase type B (MAOB) polymorphisms. Remission: Eight items on the assessment are effectively used for determining symptom remission. Acute Agitation: PANSS Excited Component (PANSS-EC) is used to demonstrate the utility of sublingual asenapine for acute agitation. It’s also used as an outcome to determine treatment effectiveness of new drugs for agitation and hostility in patients with schizophrenia and other psychotic disorders. Research: Five-factor Pentagonal model of the PANSS has been found to have a biological basis and can be useful in illuminating domain specific psychopathology in schizophrenia. Schizophrenia and beyond: The PANSS is extensively used to evaluate symptomatology in other psychotic disorders, including personality disorders, affective psychoses, mania, and substance related psychopathology.
Using the Assessment The PANSS is a 33 item scale yielding separate scores along nine clinical dimensions including the positive and negative symptoms, a composite index, general psychopathology, plus 3 items assessing aggression. The PANSS’s QuikScore paper-and-pencil format is designed for simple usage and scoring. Permissions/licensing allows for easy deployment on a variety of platforms and accounts for a large portion of the PANSS’s use (see figure 2). The Pentagonal scoring method is another asset of the PANSS. It uses 25 PANSS items organized into five scales which can depict the nature of the patient’s psychopathology along five dimensions. The dimensions include: Negative, Positive, Dysphoric Mood, Activation, and Autistic Preoccupation. In addition, the accompanying SCI–PANSS, a semi-structured interview, ensures that all content areas are covered within the interview and the IQ-PANSS provides a convenient method for recording information from care workers or family members of the patient.
Your Key to Unlocking Clinical Trial Business Access to the PANSS is often a critical component to ensuring clinical trial business. Don’t miss out on this exciting opportunity to secure your ownership of this assessment.
If you would like to learn more about securing the Intellectual Property of the PANSS, please email:
Clinton Agius
Vice President, Business Development & Marketing MHS Inc.,
Clinton.agius@mhs.com
ABOUT THE AUTHORS Stanley R. Kay, Ph.D.:
In addition to his work on the PANSS, Dr. Kay also developed the Cognitive Diagnostic Battery, published over 100 peer reviewed articles, and cared for hundreds of patients.
Lewis A. Opler, M.D., Ph.D.:
Dr. Opler is a Professor of Clinical Psychiatry at Columbia University and holds the rank of Adjunct Professor of Psychiatry at the NYU School of Medicine, as well as Chief Medical Officer and Director of the Research Division of the New York State Office of Mental Health. He is the co-author of over 200 scientific publications, two books, and has been included on the prestigious Best Doctors in America list for several years. He is also the Chair of the Expert Consensus Panel for the PANSS Institute.
Abraham Fiszbein, M.D.:
Dr. Fiszbein is a Bilingual Adult, Adolescent, and Child Psychiatrist. He studied under the mentorship of Dr. Opler and participated in an intensive Research Fellowship at AECOM/MMC, where he later became an Assistant Professor of Psychiatry. He currently has a private practice in Las Cruces, NM.
OTHER CONTRIBUTORS Mark Opler, Ph.D.:
Dr. Opler serves as the Chief Scientific Officer (CSO) at ProPhase LLC and is the Executive Director of the PANSS Institute (TPI). He is also an Adjunct Assistant Professor of Psychiatry at New York University and holds the rank of Assistant Professor of Clinical Neuroscience at Columbia University Medical Center.
Paul Michael Ramirez, Ph.D.:
Dr. Ramirez is a Professor of Clinical Neuropsychology, Psychopathology, and Psychopharmacology at Long Island University in New York City where he is also the Chair. He is widely published in psychiatric journals and is the president of CNS Ratings, a rater-training company.
Leonard White, Ph.D.:
Dr. White is an assistant Professor of Psychiatry at Mount Sinai School of Medicine and is a senior clinical psychologist at the Clinical Neuroscience Center Pilgrim Psychiatric Center. He is the principal author of the Pentagonal Model for interpretation of the PANSS and has published several papers examining its validity.